Tratamento do carcinoma metastático

• Autor(a) principal: Verona, Carlos Benedito
• Data de Publicação: 2004
• Outros Autores: Zerati Filho, Miguel [UNESP], El Ammar Müller, Márcio, Almeida Calado, Adriano
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=2614; http://hdl.handle.net/11449/67702
• topic: Imunotherapy; Metastasis; Renal cell carcinoma; Treatment; alpha interferon; interleukin 2; age distribution; cancer chemotherapy; cancer combination chemotherapy; cancer hormone therapy; cancer immunotherapy; cancer incidence; cancer radiotherapy; cancer survival; clinical trial; echography; human; imaging; incidental finding; kidney carcinoma; metastasis; nephrectomy; review; sex difference; United States

The renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of life. At the time of presentation one third of the patients have advanced disease and about 50% of the patients that underwent radical nephrectomy have recurrence. With the mainstream implementation of imaging modalities, such as ultrasound, the incidental detection of RCC has dramatically increased in recent years. Patients with metastatic RCC without treatment have na average survival of 6 to 10 months, and only 10 to 20% can be expected to survive 2 years. Treatment for patients with advanced disease remains unsatisfactory and the metastatic renal cancer continue to present a therapeutic challenge systemic therapies employed in patients with this tumor include chemotherapy, hormonal therapy, and immunotherapy. The authors review the treatment strategies of the metastatic renal cell carcinoma (RCC).